The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Does Lowering Homocysteine slow the rate of memory loss in healthy older people?
Scientific title
The Effect of Homocysteine Lowering Vitamins on Cognitive Performance in healthy older people: a Randomised Controlled Trial
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Normal Ageing 93 0
Condition category
Condition code
Neurological 114 114 0 0
Studies of normal psychology, cognitive function and behaviour

Study type
Description of intervention(s) / exposure
A randomised, double-blind, placebo-controlled trial. Participants >= 65 years of age with total plasma homocysteine concentrations >=13 [micro]mol/L, and normal renal function were randomised to take a single capsule once daily, containing either a placebo (cellulose) or a combination of 1mg L-Mefolinic acid (folate), 0.5 mg cyanocobalamin and 10mg pyridoxol, over 2 years.
Intervention code [1] 33 0
Comparator / control treatment
Placebo (cellulose)
Control group

Primary outcome [1] 142 0
To determine if the rate in slowing of cognitive perfomance associated with normal ageing can be slowed by lowering homocysteine concentrations when measured by a range of tests of cognition
Timepoint [1] 142 0
At 1 and 2 years of intervention
Secondary outcome [1] 315 0
To determine if the primary outcome measure is influenced by genotype, older age, higher starting homocysteine concentration, mood state.
Timepoint [1] 315 0
After 1 and 2 years of intervention.

Key inclusion criteria
Total plasma homocysteine concentration >= 13 [micro]mol/L; not taking supplementary folic acid or vitamins B-12 or B-6; no prior stroke; not diabetic; no established dementia; not taking folate inhibiting medications (antiepileptics, oral hypoglycaemics, treatment for depression); have normal renal function (creatinine clearance <133 [micro]mol/L in men and < 115 [micro]mol/L in women); availble for at least 2 years.
Minimum age
65 Years
Maximum age
Not stated
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
No exclusion criteria

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation to a group made by a statistician in the Dept of Social and Preventive Medicine (outside Dept Human Nutrition). Capsule packaging done in Switzerland (Eprova); code to capsules held in Switzerland, and sealed and in a locked cabinet in Dunedin till completion of the trial.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Before randomisation the sample was stratified using the median values of age and homocysteine concentration. Random numbers between 0 and 1 were generated for each person in each of the 4 groups. Those with random numbers below the median in each group were assigned to group B, and the remainder to group A.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 127 0
New Zealand
State/province [1] 127 0

Funding & Sponsors
Funding source category [1] 156 0
Name [1] 156 0
University of Otago; Otago Research Grant;
Address [1] 156 0
Country [1] 156 0
New Zealand
Funding source category [2] 157 0
Commercial sector/Industry
Name [2] 157 0
Bristol Myers Squibb Mead Johnson Unrestricted Grant
Address [2] 157 0
Country [2] 157 0
Primary sponsor type
University of Otago
New Zealand
Secondary sponsor category [1] 111 0
Name [1] 111 0
Dr R Moser
Address [1] 111 0
Country [1] 111 0
Secondary sponsor category [2] 112 0
Commercial sector/Industry
Name [2] 112 0
Eprova AG
Address [2] 112 0
Country [2] 112 0
Secondary sponsor category [3] 113 0
Commercial sector/Industry
Name [3] 113 0
CH-8200 Schaffhausen for all capsules
Address [3] 113 0
Country [3] 113 0
Secondary sponsor category [4] 114 0
Commercial sector/Industry
Name [4] 114 0
Axis-Shield, Norway for holotranscobalamin II analysis kits
Address [4] 114 0
Country [4] 114 0

Ethics approval
Ethics application status

Brief summary
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 35903 0
Address 35903 0
Country 35903 0
Phone 35903 0
Fax 35903 0
Email 35903 0
Contact person for public queries
Name 9222 0
Jennifer McMahon
Address 9222 0
Department of Human Nutrition
University of Otago
P.O. Box 56
Dunedin Otago 9001
Country 9222 0
New Zealand
Phone 9222 0
+64 3 4797959
Fax 9222 0
Email 9222 0
Contact person for scientific queries
Name 150 0
Jennifer McMahon
Address 150 0
Department of Human Nutrition
University of Otago
P.O. Box 56
Dunedin Otago 9001
Country 150 0
New Zealand
Phone 150 0
+64 3 4797959
Fax 150 0
Email 150 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary